參考文獻 |
[1] 衛生福利部國民健康署, 106年癌症發生資料. 2017:P. 9-16
[2] Giuliano, A. E., Edge, S. B., & Hortobagyi, G. N. (2018). of the AJCC cancer staging manual: breast cancer. Annals of surgical oncology, 25(7), 1783-1785.
[3] Stage, I. A., Stage, I. B., Stage, I. I. A., Stage, I. I. B., Stage, I. I. I. A., Stage, I. I. I. B., & Stage, I. V. (2009). Breast cancer staging. American joint committee on cancer.
[4] Yersal, O., & Barutca, S. (2014). Biological subtypes of breast cancer: Prognostic and therapeutic implications. World journal of clinical oncology, 5(3), 412.
[5] Kang, H. J., Yi, Y. W., Hong, Y. B., Kim, H. J., Jang, Y. J., Seong, Y. S., & Bae, I. (2014). HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction. Scientific reports, 4(1), 1-7.
[6] Kiess, A. P., McArthur, H. L., Mahoney, K., Patil, S., Morris, P. G., Ho, A., ... & McCormick, B. (2012). Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast‐conservation therapy for lymph node‐negative, human epidermal growth factor receptor 2‐positive breast cancer. Cancer, 118(8), 1982-1988.
[7] Ellis, L. M., & Hicklin, D. J. (2008). VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature reviews cancer, 8(8), 579-591.
[8] Komoto, M., Nakata, B., Nishii, T., Kawajiri, H., Shinto, O., Amano, R., ... & Hirakawa, K. (2010). In vitro and in vivo evidence that a combination of lapatinib plus S‐1 is a promising treatment for pancreatic cancer. Cancer science, 101(2), 468-473.
[9] Juranic, Z. D., Neskovic-Konstantinovic, Z., Stanojkovic, T. P., Zizak, Z., Srdic, T., Stanojevic-Bakic, N., ... & Jovanovic, D. (2005). The antitumor immune response in HER-2 positive, metastatic breast cancer patients. Journal of translational medicine, 3(1), 1-7.
[10] Roelandts, R. (2002). The history of phototherapy: something new under the sun?. Journal of the American Academy of Dermatology, 46(6), 926-930.
[11] Bown, S. G. (1983). Phototherapy of tumors. World journal of surgery, 7(6), 700-709.
[12] Hemmer, E., Benayas, A., Légaré, F., & Vetrone, F. (2016). Exploiting the biological windows: current perspectives on fluorescent bioprobes emitting above 1000 nm. Nanoscale Horizons, 1(3), 168-184.
[13] Sibuyi, N. R. S., Moabelo, K. L., Meyer, M., Onani, M. O., Dube, A., & Madiehe, A. M. (2019). Nanotechnology advances towards development of targeted-treatment for obesity. Journal of nanobiotechnology, 17(1), 1-21.
[14] Yuan, H., Khoury, C. G., Wilson, C. M., Grant, G. A., Bennett, A. J., & Vo-Dinh, T. (2012). In vivo particle tracking and photothermal ablation using plasmon-resonant gold nanostars. Nanomedicine: Nanotechnology, Biology and Medicine, 8(8), 1355-1363.
[15] Liu, P. Y., Miao, Z. H., Li, K., Yang, H., Zhen, L., & Xu, C. Y. (2018). Biocompatible Fe3+–TA coordination complex with high photothermal conversion efficiency for ablation of cancer cells. Colloids and Surfaces B: Biointerfaces, 167, 183-190.
[16] Jaque, D., Maestro, L. M., Del Rosal, B., Haro-Gonzalez, P., Benayas, A., Plaza, J. L., ... & Solé, J. G. (2014). Nanoparticles for photothermal therapies. nanoscale, 6(16), 9494-9530.
[17] Huang, X., Jain, P. K., El-Sayed, I. H., & El-Sayed, M. A. (2008). Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers in medical science, 23(3), 217-228.
[18] Moon, H. K., Lee, S. H., & Choi, H. C. (2009). In vivo near-infrared mediated tumor destruction by photothermal effect of carbon nanotubes. ACS nano, 3(11), 3707-3713.
[19] Liu, J., Dong, J., Zhang, T., & Peng, Q. (2018). Graphene-based nanomaterials and their potentials in advanced drug delivery and cancer therapy. Journal of controlled release, 286, 64-73.
[20] Jung, H. S., Verwilst, P., Sharma, A., Shin, J., Sessler, J. L., & Kim, J. S. (2018). Organic molecule-based photothermal agents: an expanding photothermal therapy universe. Chemical Society Reviews, 47(7), 2280-2297.
[21] Tegos, G., Dai, T., Fuchs, B. B., Coleman, J. J., Prates, R. A., Astrakas, C., ... & Hamblin, M. R. (2012). Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Frontiers in microbiology, 3, 120.
[22] Calixto, G. M. F., Bernegossi, J., De Freitas, L. M., Fontana, C. R., & Chorilli, M. (2016). Nanotechnology-based drug delivery systems for photodynamic therapy of cancer: a review. Molecules, 21(3), 342.
[23] Bellnier, D. A., Greco, W. R., Loewen, G. M., Nava, H., Oseroff, A. R., & Dougherty, T. J. (2006). Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a (Photochlor) and 5‐ALA‐induced protoporphyrin IX. Lasers in Surgery and Medicine: The Official Journal of the American Society for Laser Medicine and Surgery, 38(5), 439-444.
[24] Wang, K., Tu, Y., Yao, W., Zong, Q., Xiao, X., Yang, R. M., ... & Yuan, Y. (2020). Size-switchable nanoparticles with self-destructive and tumor penetration characteristics for site-specific phototherapy of cancer. ACS applied materials & interfaces, 12(6), 6933-6943.
[25] Goldberg, S. N., Gazelle, G. S., & Mueller, P. R. (2000). Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. American journal of roentgenology, 174(2), 323-331.
[26] Hou, X., Tao, Y., Pang, Y., Li, X., Jiang, G., & Liu, Y. (2018). Nanoparticle‐based photothermal and photodynamic immunotherapy for tumor treatment. International journal of cancer, 143(12), 3050-3060.
[27] Rajian, J. R., Fabiilli, M. L., Fowlkes, J. B., Carson, P. L., & Wang, X. (2011). Drug delivery monitoring by photoacoustic tomography with an ICG encapsulated double emulsion. Optics express, 19(15), 14335-14347.
[28] Kaplan-Marans, E., Fulla, J., Tomer, N., Bilal, K., & Palese, M. (2019). Indocyanine green (ICG) in urologic surgery. Urology, 132, 10-17.
[29] Alius, C., Oprescu, S., Balalau, C., & Nica, A. E. (2018). Indocyanine green enhanced surgery; principle, clinical applications and future research directions. Journal of Clinical and Investigative Surgery, 3(1), 1-8.
[30] Hill, T. K., & Mohs, A. M. (2016). Image‐guided tumor surgery: will there be a role for fluorescent nanoparticles?. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 8(4), 498-511.
[31] Desmettre, T., Devoisselle, J. M., & Mordon, S. (2000). Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Survey of ophthalmology, 45(1), 15-27.
[32] Miwa, M. (2010). The principle of ICG fluorescence method. The Open Surgical Oncology Journal, 2(1).
[33] Manchanda, R., Fernandez-Fernandez, A., Nagesetti, A., & McGoron, A. J. (2010). Preparation and characterization of a polymeric (PLGA) nanoparticulate drug delivery system with simultaneous incorporation of chemotherapeutic and thermo-optical agents. Colloids and Surfaces B: Biointerfaces, 75(1), 260-267.
[34] Kosaka, N., Mitsunaga, M., Longmire, M. R., Choyke, P. L., & Kobayashi, H. (2011). Near infrared fluorescence‐guided real‐time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green. International journal of cancer, 129(7), 1671-1677.
[35] Shirata, C., Kaneko, J., Inagaki, Y., Kokudo, T., Sato, M., Kiritani, S., ... & Kokudo, N. (2017). Near-infrared photothermal/photodynamic therapy with indocyanine green induces apoptosis of hepatocellular carcinoma cells through oxidative stress. Scientific reports, 7(1), 1-8.
[36] Riefke, B., Licha, K., Semmler, W., Nolte, D., Ebert, B., & Rinneberg, H. H. (1996, December). In vivo characterization of cyanine dyes as contrast agents for near-infrared imaging. In Optical and Imaging Techniques for Biomonitoring II (Vol. 2927, pp. 199-208). International Society for Optics and Photonics.
[37] Joh, J. H., Park, H. C., Han, S. A., & Ahn, H. J. (2016). Intraoperative indocyanine green angiography for the objective measurement of blood flow. Annals of surgical treatment and research, 90(5), 279-286.
[38] Saxena, V., Sadoqi, M., & Shao, J. (2004). Enhanced photo-stability, thermal-stability and aqueous-stability of indocyanine green in polymeric nanoparticulate systems. Journal of Photochemistry and Photobiology B: Biology, 74(1), 29-38.
[39] Liu, L. F., Desai, S. D., LI, T. K., Mao, Y., Sun, M. E. I., & SIM, S. P. (2000). Mechanism of action of camptothecin. Annals of the New York Academy of Sciences, 922(1), 1-10.
[40] Wen, Y., Wang, Y., Liu, X., Zhang, W., Xiong, X., Han, Z., & Liang, X. (2017). Camptothecin-based nanodrug delivery systems. Cancer biology & medicine, 14(4), 363.
[41] Liu, Y. Q., Li, W. Q., Morris‐Natschke, S. L., Qian, K., Yang, L., Zhu, G. X., ... & Lee, K. H. (2015). Perspectives on biologically active camptothecin derivatives. Medicinal research reviews, 35(4), 753-789.
[42] Burke, T. G., Mishra, A. K., Wani, M. C., & Wall, M. E. (1993). Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry, 32(20), 5352-5364.
[43] Ci, T., Li, T., Chang, G., Yu, L., & Ding, J. (2013). Simply mixing with poly (ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family. Journal of Controlled Release, 169(3), 329-335.
[44] Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., ... & Collina, S. (2017). The long story of camptothecin: From traditional medicine to drugs. Bioorganic & Medicinal Chemistry Letters, 27(4), 701-707.
[45] Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004). Camptothecin: current perspectives. Bioorganic & medicinal chemistry, 12(7), 1585-1604.
[46] Mathijssen, R. H., Loos, W. J., Verweij, J., & Sparreboom, A. (2002). Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Current cancer drug targets, 2(2), 103-123.
[47] Hu, T., Liu, C., Li, Q., Xiong, J., Ma, Y., Wu, G., & Zhao, Y. (2018). Apatinib+ CPT-11+ S-1 for treatment of refractory brain metastases in patient with triple-negative breast cancer: case report and literature review. Medicine, 97(15).
[48] Riess, J. G. (2005). Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artificial cells, blood substitutes, and biotechnology, 33(1), 47-63.
[49] Lowe, K. C. (2006). Fluosol®: The first commercial injectable perfluorocarbon oxygen carrier. In Blood substitutes (pp. 276-287). Academic Press.
[50] Jacoby, C., Temme, S., Mayenfels, F., Benoit, N., Krafft, M. P., Schubert, R., ... & Flögel, U. (2014). Probing different perfluorocarbons for in vivo inflammation imaging by 19F MRI: image reconstruction, biological half‐lives and sensitivity. NMR in Biomedicine, 27(3), 261-271.
[51] Al Rifai, N., Desgranges, S., Le Guillou-Buffello, D., Giron, A., Urbach, W., Nassereddine, M., ... & Taulier, N. (2020). Ultrasound-triggered delivery of paclitaxel encapsulated in an emulsion at low acoustic pressures. Journal of Materials Chemistry B, 8(8), 1640-1648.
[52] Li, N., Xu, F., Cheng, J., Zhang, Y., Huang, G., Zhu, J., ... & He, D. (2018). Perfluorocarbon nanocapsules improve hypoxic microenvironment for the tumor ultrasound diagnosis and photodynamic therapy. Journal of biomedical nanotechnology, 14(12), 2162-217. |